Canada Pension Plan Investment Board increased its position in Endo International PLC (NASDAQ:ENDP) by 93.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 565,240 shares of the company’s stock after buying an additional 273,024 shares during the period. Canada Pension Plan Investment Board owned approximately 0.25% of Endo International PLC worth $6,314,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in ENDP. OppenheimerFunds Inc. boosted its stake in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock worth $32,065,000 after buying an additional 1,857,678 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock worth $25,345,000 after buying an additional 633,904 shares during the last quarter. First Quadrant L P CA bought a new stake in shares of Endo International PLC during the first quarter worth $24,556,000. Schneider Capital Management Corp boosted its stake in shares of Endo International PLC by 14.9% in the first quarter. Schneider Capital Management Corp now owns 642,311 shares of the company’s stock worth $7,168,000 after buying an additional 83,100 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in shares of Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock worth $6,185,000 after buying an additional 483,545 shares during the last quarter. Institutional investors and hedge funds own 92.27% of the company’s stock.
Endo International PLC (ENDP) opened at 8.72 on Monday. The company’s market capitalization is $1.95 billion. The firm’s 50-day moving average price is $10.47 and its 200-day moving average price is $11.43. Endo International PLC has a 52 week low of $7.41 and a 52 week high of $24.93.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. During the same quarter in the previous year, the business earned $0.86 EPS. The firm’s revenue was down 4.9% on a year-over-year basis. On average, equities analysts expect that Endo International PLC will post $3.52 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://stocknewstimes.com/2017/08/21/canada-pension-plan-investment-board-boosts-stake-in-endo-international-plc-endp.html.
A number of analysts have recently weighed in on ENDP shares. Zacks Investment Research upgraded Endo International PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, May 2nd. ValuEngine cut Endo International PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Endo International PLC in a research report on Tuesday, August 8th. Deutsche Bank AG dropped their price target on Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, July 7th. Finally, BMO Capital Markets reiterated a “hold” rating and set a $16.00 price target on shares of Endo International PLC in a research report on Wednesday, May 17th. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $14.75.
In other news, CFO Blaise Coleman purchased 6,500 shares of the firm’s stock in a transaction dated Tuesday, August 15th. The stock was bought at an average price of $7.89 per share, with a total value of $51,285.00. Following the acquisition, the chief financial officer now directly owns 13,729 shares of the company’s stock, valued at $108,321.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Terrance J. Coughlin purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was purchased at an average cost of $7.70 per share, with a total value of $154,000.00. Following the acquisition, the chief operating officer now directly owns 181,369 shares in the company, valued at $1,396,541.30. The disclosure for this purchase can be found here. Insiders bought a total of 36,000 shares of company stock valued at $279,460 in the last three months. 0.50% of the stock is owned by company insiders.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International PLC (NASDAQ:ENDP).
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.
